Gamble Jones Investment Counsel Cuts Stake in Merck & Co., Inc. (NYSE:MRK)

Gamble Jones Investment Counsel lowered its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 4.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,818 shares of the company’s stock after selling 747 shares during the quarter. Gamble Jones Investment Counsel’s holdings in Merck & Co., Inc. were worth $1,500,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in MRK. Titan Capital Management LLC CA bought a new position in Merck & Co., Inc. during the second quarter valued at approximately $25,000. LFA Lugano Financial Advisors SA boosted its stake in Merck & Co., Inc. by 250.0% during the second quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock valued at $26,000 after buying an additional 225 shares during the last quarter. JJJ Advisors Inc. bought a new position in Merck & Co., Inc. during the second quarter valued at approximately $27,000. Cumberland Partners Ltd bought a new position in Merck & Co., Inc. during the second quarter valued at approximately $40,000. Finally, Fusion Family Wealth LLC boosted its stake in Merck & Co., Inc. by 268.2% during the second quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock valued at $41,000 after buying an additional 354 shares during the last quarter. Hedge funds and other institutional investors own 74.95% of the company’s stock.

Shares of NYSE:MRK traded up $0.71 during trading on Friday, hitting $83.59. The company had a trading volume of 6,053,527 shares, compared to its average volume of 10,105,755. The stock has a market cap of $212.31 billion, a price-to-earnings ratio of 19.26, a price-to-earnings-growth ratio of 1.80 and a beta of 0.54. Merck & Co., Inc. has a one year low of $70.89 and a one year high of $87.35. The company has a fifty day simple moving average of $84.01 and a two-hundred day simple moving average of $82.77. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.21 and a quick ratio of 0.92.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $1.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.27. The business had revenue of $12.40 billion during the quarter, compared to analyst estimates of $11.59 billion. Merck & Co., Inc. had a return on equity of 47.94% and a net margin of 20.26%. The company’s revenue for the quarter was up 14.9% on a year-over-year basis. During the same period last year, the company earned $1.19 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

MRK has been the subject of a number of research reports. Credit Suisse Group reissued a “buy” rating and set a $95.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, August 7th. JPMorgan Chase & Co. set a $96.00 price target on Merck & Co., Inc. and gave the company a “buy” rating in a research note on Thursday, October 10th. ValuEngine lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Bank of America initiated coverage on Merck & Co., Inc. in a research note on Wednesday, October 16th. They set a “neutral” rating and a $90.00 price target for the company. Finally, Leerink Swann assumed coverage on Merck & Co., Inc. in a research note on Thursday, August 15th. They set an “outperform” rating and a $103.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $95.13.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Further Reading: How is Preferred Stock Different from Common Stock?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Leave a Reply

Your email address will not be published. Required fields are marked *

*